MX347741B - Opioides pegilados con bajo potencial de abuso. - Google Patents

Opioides pegilados con bajo potencial de abuso.

Info

Publication number
MX347741B
MX347741B MX2011002748A MX2011002748A MX347741B MX 347741 B MX347741 B MX 347741B MX 2011002748 A MX2011002748 A MX 2011002748A MX 2011002748 A MX2011002748 A MX 2011002748A MX 347741 B MX347741 B MX 347741B
Authority
MX
Mexico
Prior art keywords
abuse
opioids
pegylated
low potential
opioid agonists
Prior art date
Application number
MX2011002748A
Other languages
English (en)
Spanish (es)
Other versions
MX2011002748A (es
Inventor
C Simone Jude-Fishburn
Timothy A Riley
Alberto Zacarias
Hema Gursahani
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/558,395 external-priority patent/US8173666B2/en
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2011002748A publication Critical patent/MX2011002748A/es
Publication of MX347741B publication Critical patent/MX347741B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2011002748A 2008-09-16 2009-09-16 Opioides pegilados con bajo potencial de abuso. MX347741B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19224708P 2008-09-16 2008-09-16
US12/558,395 US8173666B2 (en) 2007-03-12 2009-09-11 Oligomer-opioid agonist conjugates
PCT/US2009/005174 WO2010033195A1 (en) 2008-09-16 2009-09-16 Pegylated opioids with low potential for abuse

Publications (2)

Publication Number Publication Date
MX2011002748A MX2011002748A (es) 2011-04-21
MX347741B true MX347741B (es) 2017-05-10

Family

ID=41611345

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011002748A MX347741B (es) 2008-09-16 2009-09-16 Opioides pegilados con bajo potencial de abuso.

Country Status (10)

Country Link
US (2) US20110237614A1 (enExample)
EP (2) EP3342427A1 (enExample)
JP (1) JP5827123B2 (enExample)
KR (1) KR101660996B1 (enExample)
CN (1) CN102159249A (enExample)
AU (1) AU2009292631A1 (enExample)
CA (1) CA2734333A1 (enExample)
IL (1) IL211762A (enExample)
MX (1) MX347741B (enExample)
WO (1) WO2010033195A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
EP2932964A1 (en) 2000-10-30 2015-10-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
CA2768392C (en) * 2009-07-21 2018-04-17 Nektar Therapeutics Oligomer-opioid agonist conjugates
US20130023553A1 (en) * 2010-01-12 2013-01-24 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク． メトプロロールを含むアルコール耐性持続放出性経口剤形
US10525054B2 (en) 2011-11-07 2020-01-07 Inheris Biopharma, Inc. Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound
AU2012336030B2 (en) 2011-11-07 2017-09-14 Nektar Therapeutics Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound
EP2895457B1 (en) 2012-09-17 2020-05-20 Nektar Therapeutics Oligomer-containing benzamide-based compounds
MX367773B (es) 2012-10-30 2019-09-05 Nektar Therapeutics Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
CA2881144A1 (en) * 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
US9815824B2 (en) * 2013-06-28 2017-11-14 Nektar Therapeutics Kappa opioid agonists and uses thereof
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2017041095A1 (en) 2015-09-03 2017-03-09 Allegheny-Singer Research Institute Hydrophilic fentanyl derivatives
CN107019803B (zh) * 2016-01-29 2020-09-15 北京键凯科技股份有限公司 具有低成瘾作用的聚乙二醇化阿片样物质
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN108210933B (zh) * 2016-12-22 2021-05-04 北京键凯科技股份有限公司 一种地佐辛与聚乙二醇的结合物
JP7369687B2 (ja) * 2017-07-20 2023-10-26 スーチョウ ランシンダタイ ファーマシューティクス エルティーディー シーオー． 乱用防止長期作用型徐放性オピオイドプロドラッグ
WO2019189188A1 (ja) 2018-03-29 2019-10-03 日油株式会社 トリチル基含有単分散ポリエチレングリコールの精製方法
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN115181109B (zh) * 2021-04-02 2024-06-04 南京正大天晴制药有限公司 吗啡喃衍生物的晶体及其制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2654756A (en) * 1949-10-20 1953-10-06 Mallinckrodt Chemical Works Process of preparing codeinone, dihydrocodeinone, and dihydromorphinone
US2628962A (en) * 1949-10-20 1953-02-17 Mallinckrodt Chemical Works Method for preparing dihydrocodeinone, dihydromorphinone, and codeinone
US2715626A (en) * 1950-07-05 1955-08-16 Merck & Co Inc Process of preparing dihydrocodeinone
US2649454A (en) 1951-08-20 1953-08-18 Univ California Method for preparing dihydromorphinone, dihydrocodeinone, and dihydropseudocodeinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3254088A (en) * 1961-03-14 1966-05-31 Lewenstein Morphine derivative
JPS60149589A (ja) * 1984-01-14 1985-08-07 Daiichi Rajio Isotope Kenkyusho:Kk クラウン化コデイノン類
US5843900A (en) * 1991-04-01 1998-12-01 Cortech, Inc. Bradykinin antagonists
DE4132159A1 (de) * 1991-09-27 1993-04-01 Boehringer Ingelheim Kg 14-hydroxy-n-(2-methoxyethyl)-7,8-dihydromorphin und -norisomorphin, verfahren zu deren herstellung und deren verwendung als arzneimittel
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6004577A (en) * 1997-08-12 1999-12-21 Murdock; Thomas O. Enhanced electrotransport of therapeutic agents having polybasic anionic counter ions
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
WO2001024831A2 (en) * 1999-10-04 2001-04-12 Shearwater Corporation Polymer stabilized neuropeptides
US20050233459A1 (en) * 2003-11-26 2005-10-20 Melker Richard J Marker detection method and apparatus to monitor drug compliance
US7049326B2 (en) * 2000-05-12 2006-05-23 The University Of Toledo Method and compositions for temporarily incapacitating subjects
DE10025946A1 (de) * 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
US20070258894A1 (en) * 2000-11-08 2007-11-08 Melker Richard J System and Method for Real-Time Diagnosis, Treatment, and Therapeutic Drug Monitoring
US20020106331A1 (en) * 2000-12-08 2002-08-08 Joan Rosell Use of electrolytes (ions in solution) to suppress charging of inhalation aerosols
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20030022876A1 (en) * 2001-06-05 2003-01-30 Ashton Paul A. Sustained-release analgesic compounds
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
DK2939696T3 (en) * 2001-10-18 2016-05-23 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
ATE358275T1 (de) * 2001-11-16 2007-04-15 Randox Lab Ltd Verfahren und kit zum nachweis, oder zum quantifizieren von, metaboliten von fentanyl und metaboliten von fentanyl analoga
FR2832311B1 (fr) * 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
JP2006520392A (ja) * 2003-03-13 2006-09-07 コントロールド・ケミカルズ・インコーポレーテッド 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法
EP1782834A3 (en) * 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
DK1694363T3 (en) * 2003-12-16 2014-03-24 Nektar Therapeutics Monodisperse PEGylated Naloxole Compositions
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
JP2007532645A (ja) * 2004-04-13 2007-11-15 アルザ コーポレイション フェンタニルに基づく薬剤の経皮送達システム用の器具および方法
PE20060598A1 (es) * 2004-09-13 2006-08-21 Ono Pharmaceutical Co Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
EP1931417A2 (en) * 2005-09-30 2008-06-18 Transcutaneous Technologies Inc. Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles
EP2010539B1 (en) * 2006-04-21 2017-06-14 Nektar Therapeutics Stereoselective reduction of a morphinone
KR20090031519A (ko) * 2006-05-26 2009-03-26 파마코포어, 인크. 페놀계 오피오이드의 제어 방출
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US7511054B2 (en) * 2006-09-22 2009-03-31 Alltranz Inc. Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
JP2010509227A (ja) * 2006-11-07 2010-03-25 ネクター セラピューティックス エイエル，コーポレイション オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与
EP2650303A1 (en) * 2007-02-26 2013-10-16 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
US8173666B2 (en) * 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
EP2134371B1 (en) * 2007-03-12 2015-01-14 Nektar Therapeutics Oligomer-opioid agonist conjugates
WO2009094209A1 (en) * 2008-01-25 2009-07-30 Nektar Therapeutics Al, Corporation Oligomer-diarylpiperazine conjugates
JP2011515495A (ja) * 2008-03-26 2011-05-19 オールトランツ インコーポレイティド オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑制経皮製剤
US11033631B2 (en) * 2008-06-09 2021-06-15 Nektar Therapeutics Methods of treating CYP2D6 alternative metabolizers
US20100016365A1 (en) * 2008-07-17 2010-01-21 Auspex Pharmaceuticals, Inc. Substituted 4-amino-piperidines
CN102159193B (zh) * 2008-09-18 2015-09-16 普渡制药公司 包含聚(ε-己内酯)的药物剂型
US20130023553A1 (en) * 2010-01-12 2013-01-24 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects

Also Published As

Publication number Publication date
JP2012502904A (ja) 2012-02-02
JP5827123B2 (ja) 2015-12-02
EP3342427A1 (en) 2018-07-04
IL211762A (en) 2016-06-30
US20160243111A1 (en) 2016-08-25
KR101660996B1 (ko) 2016-09-28
EP2340044A1 (en) 2011-07-06
WO2010033195A1 (en) 2010-03-25
CN102159249A (zh) 2011-08-17
CA2734333A1 (en) 2010-03-25
US20110237614A1 (en) 2011-09-29
KR20110058783A (ko) 2011-06-01
IL211762A0 (en) 2011-06-30
MX2011002748A (es) 2011-04-21
AU2009292631A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
MX347741B (es) Opioides pegilados con bajo potencial de abuso.
EP2305214A4 (en) NEW MOLECULAR ARRANGEMENT, MOLECULAR PROBE FOR MOLECULAR IMAGING AND MOLECULAR PROBE FOR A DRUG DELIVERY SYSTEM, AND MOLECULAR IMAGING SYSTEM AND DRUG DISPENSING SYSTEM
IL184399A0 (en) Content delivery system
IL210185A0 (en) Methods, compositions and systems for local delivery of drugs
MY158890A (en) Pegylated insulin lispro compounds
GB2442875B (en) Regulated drug delivery system
ZA201002014B (en) Drug delivery system
GB0805703D0 (en) Apparatus, systems and methods for targeted content delivery
IL210590A0 (en) Progestin-cotaining drug delivery system
EP2299989A4 (en) STERILIZED TRANSDERMAL DRUG DELIVERY SYSTEM
EP1888001A4 (en) TRANSDERMAL STAMP FOR THE DELIVERY OF MEDICINAL PRODUCTS
GB0619385D0 (en) Targeted content delivery for networks
GB0602562D0 (en) Content Delivery
IL198911A0 (en) Drug delivery
WO2007122464A8 (en) Marking feed items in mobile terminals for further viewing
PL2101740T3 (pl) Nowa, niepodatna na nadużycie kompozycja farmaceutyczna zawierająca opioidy
EP2029292A4 (en) DISTRIBUTION SYSTEM WITH SURPRISED SPONGE
PL2117521T3 (pl) Transdermalne systemy dostarczania zawierające bupiwakainę
EP1901796A4 (en) DRUG DELIVERY SYSTEM
EP2010162A4 (en) COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
EP2194068A4 (en) CYCLODEXTRIN COMPOUNDS MODIFIED WITH FOLYIC ACID, METHOD FOR THE PRODUCTION THEREOF, ACTIVE EXTRACTS FOR A TARGETED ACTIVE COMPOSITION SYSTEM, PHARMACEUTICAL COMPOSITION AND IMAGING AGENTS
AP2011005687A0 (en) Sustained release drug delivery system.
IL212357A0 (en) Sustained drug delivery system
EP1858483A4 (en) SYSTEM FOR THE DELIVERY OF MULTIPLE MEDICAMENTS
GB0605130D0 (en) Apparatus for location-based information delivery

Legal Events

Date Code Title Description
FG Grant or registration